| View |
|
BR-1458
|
Tremelimumab
|
Imjudo
|
300 mg/15 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
Monitored Release
|
20 December 2023
|
20 December 2028
|
| View |
|
BR-1459
|
Tremelimumab
|
Imjudo
|
25 mg/1.25 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
Monitored Release
|
20 December 2023
|
20 December 2028
|
| View |
|
BR-1460
|
Infliximab
|
Remsima
|
120 mg
|
Solution For Injection
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1461
|
Ocrelizumab
|
Ocrevus
|
300 mg/10 ml (30 mg/ml)
|
oncentrate for Solution for
Intravenous Infusion
|
-
|
F. Hoffmann-La Roche Ltd.
|
Switzerland
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1462
|
Ocrelizumab
|
Ocrevus
|
300 mg/10 ml (30 mg/ml)
|
Concentrate for Solution for
Intravenous Infusion.
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Monitored Release
|
22 December 2023
|
22 December 2028
|
| View |
|
BR-1463
|
Trastuzumab
|
Hertumab
|
150 mg
|
Powder for Concentrate for Solution for Infusion.
(IV)
|
-
|
Shanghai Henlius Biopharmaceutical Co., Ltd.
|
China
|
Initial
|
04 January 2024
|
04 January 2029
|
| View |
|
BR-1464
|
Trastuzumab deruxtecan
|
Enhertu
|
100 mg
|
Powder for Concentrate for Solution for Infusion (IV)
|
-
|
Baxter Oncology GmbH
|
Germany
|
Monitored Release
|
15 January 2024
|
15 January 2029
|
| View |
|
BR-1465
|
Japanese Encephalitis Vaccine (Inactivated, Adsorbed)
|
Jeev
|
6 mcg/0.5 mL
|
Suspension for Injection (IM)
|
Vaccines
|
Biological E. Limited
|
India
|
Monitored Release (MR) [Reapplication]
|
08 February 2024
|
08 February 2029
|
| View |
|
BR-1466
|
Anifrolumab
|
Saphnelo
|
300 mg/2 mL (150 mg/ml)
|
Concentrate for Solution for
Infusion (IV)
|
Monoclonal Antibody.
|
AstraZeneca Nijmegen B.V.
|
Netherlands
|
Monitored Release
|
14 February 2024
|
14 February 2029
|
| View |
|
BR-1467
|
Avelumab
|
Bavencio
|
200 mg/10 mL (20 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Monoclonal Antibodies
|
Merck Serono SA
|
Switzerland
|
Monitored Release (MR)
|
22 February 2024
|
22 February 2029
|
| View |
|
BR-1468
|
Semaglutide
|
Wegovy
|
0.25 mg/0.37 mL (0.68 mg/mL)
|
Solution
Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1469
|
Semaglutide
|
Wegovy
|
2.4 mg/ 0.75 mL (3.2 mg/mL)
|
Solution for
Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1470
|
Semaglutide
|
Wegovy
|
0.5 mg/0.37 mL (1.34 mg/mL)
|
Solution for
Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1471
|
Semaglutide
|
Wegovy
|
1 mg/0.75 mL (1.34 mg/mL)
|
Solution for Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues.
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1472
|
Semaglutide
|
Wegovy
|
1.7 mg/ 0.75 mL (2.27 mg/mL)
|
Solution for Injection (SC)
|
Glucagon-like peptide (GLP-1) Analogues
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (MR)
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1478
|
Rituximab
|
Rituxell
|
10 mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Joint Stock Company Biocad
|
Russia
|
Initial
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1479
|
Bevacizumab
|
Bevalast
|
25 mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Monoclonal Antibodies
|
Joint Stock Company Biocad
|
Russia
|
Initial
|
28 February 2024
|
28 February 2029
|
| View |
|
BR-1480
|
Spesolimab
|
Spevigo
|
450 mg/7.5 mL (60 mg/mL)
|
Concentrate for Solution for
Infusion (IV)
|
Interleukin inhibitors
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Monitored Release (MR)
|
05 April 2024
|
05 April 2029
|
| View |
|
BR-220
|
Rabbies Vaccine (Inactivated)(Wistar Strain Rabies)
|
Verorab
|
2.5 IU/ 0.5 mL
|
Powder For Suspension(ID/IM)
|
-
|
Sanofi Pasteur, Inc.
|
France
|
Renewal
|
26 May 2023
|
10 December 2027
|
| View |
|
BR-280
|
Typhoid Polysaccharide Vaccine
|
Typhim Vi
|
Formulation: Each dose (0.5 mL) contains: Purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain)...................... 25 mcg
|
Solution for Injection (IM/SC)
|
-
|
Sanofi Pasteur
|
France
|
-
|
18 March 2022
|
01 March 2027
|